Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | APAF1 | O14727 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442758 | 0.86 | MEN1 (0.45) | KDM4ERXFP1ALDH1A1HPGDGLA | |
| SCHEMBL5439314 | 0.77 | KDM4E (0.39) | KDM4ERXFP1GAA | |
| SCHEMBL5442753 | 0.76 | FASN (0.35) | KDM4EGAAALDH1A1HPGDGLA | |
| SCHEMBL6313538 | 0.73 | APAF1 (0.56) | KDM4ERXFP1GAAALDH1A1HPGD | |
| SCHEMBL10855118 | 0.71 | KDM4E (0.56) | KDM4ERXFP1GAAALDH1A1HPGD | |
| SCHEMBL5444551 | 0.71 | GSK3B (0.41) | KDM4EGAAALDH1A1HPGDGLA | |
| SCHEMBL5441254 | 0.70 | PARP1 (0.35) | KDM4EGAAALDH1A1HPGDGLA | |
| SCHEMBL5444613 | 0.68 | GAA (0.35) | KDM4ERXFP1GAAALDH1A1HPGD | |
| SCHEMBL6311054 | 0.65 | KDM4E (0.56) | KDM4EGAAALDH1A1HPGDGLA | |
| SCHEMBL6311912 | 0.63 | KDM4E (0.56) | KDM4EGAAALDH1A1HPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1717238-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | ERG28, MANBA, MAN2B1 | KDM4E 3019/4885RXFP1 4160/4885GAA 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.